Novartis sells injectables plant to Avara

May 31, 2018

Novartis announced the sale of its Quebec sterile manufacturing facility as well as the adjacent Sandoz Development Center to CDMO Avara Pharmaceutical Services.

The Boucherville plant is the largest sterile manufacturing facility for injectable medicines in Canada, supplying injectable medicines to Sandoz in Canada and the United States.

Under the terms of the deal, Sandoz Canada remains the owner of the marketing authorizations for its products manufactured by Avara, and both parties will sign a long-term supply agreement to ensure that supply, quality and service remains unchanged.

For Avara, the acquisition represents its first entry into the Canadian market and further expands its sterile processing capability.


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments